Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Enfermedades Infecciosas | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MK-4482 for the Prevention of COVID-19 (Laboratory-confirmed SARS-CoV-2 Infection With Symptoms) in Adults Residing With a Person With COVID-19
INTERVENTIONAL
Inicio: 11 de ago de 2021
ID: NCT04939428
Completado
Fase 2
ClinicalTrials.gov
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study of EDP-938 Administered Orally for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Ambulatory Adult Subjects (RSVP)
INTERVENTIONAL
Inicio: 22 de ene de 2020
ID: NCT04196101
Completado
Fase 2
ClinicalTrials.gov
Antiviral Effect, Safety and Pharmacokinetics of BI 201335 NA in Hepatitis C Virus Genotype 1 Infected Treatment-naïve and Treatment-experienced Patients for 24 Weeks as Combination Therapy With Pegylated Interferon-alpha 2a and Ribavirin (Double-blinded, Randomised, Placebo-controlled, Phase II)
INTERVENTIONAL
Inicio: 1 de oct de 2008
ID: NCT00774397
Reclutando
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis
INTERVENTIONAL
Inicio: 31 de jul de 2025
ID: NCT07044297
Desconocido
ClinicalTrials.gov
Incidence of de Novo Hepatocellular Carcinoma After Direct-acting Antiviral Agents for HCV: a Multicenter Prospective Cohort Study From Latin America.
OBSERVATIONAL
Inicio: 1 de may de 2016
ID: NCT03775798
Por invitación
Fase 3
ClinicalTrials.gov
A Multicenter, Open-Label, Single-Arm, Phase 3, Long-Term Extension Study to Evaluate Continuous Safety and Efficacy of BIIB059 (Litifilimab) in Adult Participants With Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus Erythematosus With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy
INTERVENTIONAL
Inicio: 3 de oct de 2023
ID: NCT06044337
Completado
Fase 2
ClinicalTrials.gov
Phase 2, Randomized, Controlled, Open Label Multi-center Study to Assess Efficacy and Safety of DFV890 for the Treatment of SARS-CoV-2 Infected Patients With COVID-19 Pneumonia and Impaired Respiratory Function
INTERVENTIONAL
Inicio: 27 de may de 2020
ID: NCT04382053
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of Eravacycline Compared With Ertapenem in Complicated Intra-abdominal Infections
INTERVENTIONAL
Inicio: 1 de ago de 2013
ID: NCT01844856
Desconocido
ClinicalTrials.gov
Effectiveness of Implementing a Strategy to Re-linkage to Care of Patients With Hepatitis C Who Were Lost to Follow-up
OBSERVATIONAL
Inicio: 1 de sept de 2020
ID: NCT04470271
Completado
Fase 3
ClinicalTrials.gov
A Pivotal Phase 3 Study of MEDI-524 (Numax; Motavizumab), an Enhanced Potency Humanized RSV Monoclonal Antibody, for the Prophylaxis of Serious RSV Disease in High-Risk Children
INTERVENTIONAL
Inicio: 1 de nov de 2004
ID: NCT00129766
Completado
Fase 3
ClinicalTrials.gov
A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine For Pre-Exposure Prophylaxis in HIV-Uninfected Men and Transgender Women Who Have Sex With Men
INTERVENTIONAL
Inicio: 19 de dic de 2016
ID: NCT02720094
Completado
Fase 3
ClinicalTrials.gov
A Placebo-controlled, Multi-country & Multi-center Study to Assess the Efficacy, Safety & Immunogenicity of 2 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Healthy Infants
INTERVENTIONAL
Inicio: 5 de ago de 2003
ID: NCT00140673
Activo, no recluta
Fase 3
ClinicalTrials.gov
An Operationally Seamless Phase 2/3 Randomized, Open-label, Multicenter, Active-Controlled Study to Evaluate the Safety and Efficacy of Bictegravir/Lenacapavir Versus Stable Baseline Regimen in Virologically Suppressed People With HIV-1 on Stable Complex Treatment Regimens
INTERVENTIONAL
Inicio: 16 de ago de 2022
ID: NCT05502341
Completado
Fase 3
ClinicalTrials.gov
A 96 Week Study Comparing the Antiviral Efficacy and Safety of Atazanavir/Ritonavir With Lopinavir/Ritonavir, Each in Combination With Fixed Dose Tenofovir-Emtricitabine in HIV-1 Infected Treatment in Naive Subjects
INTERVENTIONAL
Inicio: 1 de nov de 2005
ID: NCT00272779
Completado
ClinicalTrials.gov
Analysis of the Impact on Surgical Residency Programs in Times of Pandemic in Argentina: A Cross-sectional Study
OBSERVATIONAL
Inicio: 15 de ago de 2020
ID: NCT04703400
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase IIIb, Multi-center, Non-randomized, Parallel-group, Open-label, Hybrid Type I Study Evaluating the Efficacy, Safety, Implementation Effectiveness, and Patient-reported Outcomes of Oral Dolutegravir/Lamivudine Once-daily as a First-line Regimen Followed by Participant-determined Optional Switch to Long-acting Intramuscular Cabotegravir Plus Rilpivirine Every Two Months for the Maintenance of Virologic Suppression in Antiretroviral Therapy Naive Adults Living With HIV-1
INTERVENTIONAL
Inicio: 6 de jul de 2023
ID: NCT05917509
Desconocido
ClinicalTrials.gov
A Dengue Sero-prevalence Study in the Metropolitan Area of Buenos Aires
OBSERVATIONAL
Inicio: 11 de sept de 2023
ID: NCT05919277
Completado
Fase 3
ClinicalTrials.gov
A PHASE 3 PROSPECTIVE, RANDOMIZED, MULTICENTER, OPEN-LABEL, CENTRAL ASSESSOR-BLINDED, PARALLEL GROUP, COMPARATIVE STUDY TO DETERMINE THE EFFICACY, SAFETY AND TOLERABILITY OF AZTREONAM-AVIBACTAM (ATM-AVI) ±METRONIDAZOLE (MTZ) VERSUS MEROPENEM±COLISTIN (MER±COL) FOR THE TREATMENT OF SERIOUS INFECTIONS DUE TO GRAM NEGATIVE BACTERIA, INCLUDING METALLO-Β-LACTAMASE (MBL) - PRODUCING MULTIDRUG RESISTANT PATHOGENS, FOR WHICH THERE ARE LIMITED OR NO TREATMENT OPTIONS
INTERVENTIONAL
Inicio: 5 de abr de 2018
ID: NCT03329092
Completado
Fase 2
ClinicalTrials.gov
A Phase 2, Randomized, Placebo-controlled, Single-blind Trial To Assess The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine When Administered In Either 2- Or 3-dose Regimens In Healthy Subjects Aged Greater Than Or Equal To 11 To <19 Years
INTERVENTIONAL
Inicio: 3 de mar de 2011
ID: NCT01299480
Completado
Fase 3
ClinicalTrials.gov
A PHASE 3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLINDED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER
INTERVENTIONAL
Inicio: 29 de mar de 2017
ID: NCT03090191
Anterior
1
...
32
33
34
...
434
Siguiente
Filtros